Literature DB >> 20652449

Knockdown of eIF4E suppresses cell growth and migration, enhances chemosensitivity and correlates with increase in Bax/Bcl-2 ratio in triple-negative breast cancer cells.

Fei-fei Zhou1, Min Yan, Gui-fang Guo, Fang Wang, Hui-juan Qiu, Fei-meng Zheng, Yan Zhang, Qiang Liu, Xiao-feng Zhu, Liang-ping Xia.   

Abstract

Elevated activity of the eukaryotic translation initiation factor 4E (eIF4E) plays crucial roles in tumorigenesis and disease progression by disproportionately increasing translation of mRNAs coding proteins that play significant roles in all aspects of malignancy, providing that eIF4E as an attractive target for therapeutic intervention. In this study, we showed that inhibition of eIF4E by small interfering RNAs (siRNA) resulted in cell cycle arrest and suppression of colony formation in MDA-MB-231 triple-negative (TN) breast cancer cells. Migration transwell assay revealed that repression of eIF4E effectively inhibited motility of MDA-MB-231 cancer cells. Importantly, we showed that silencing of eIF4E sensitized MDA-MB-231 cells to chemotherapeutic drugs of cisplatin, adriamycin, paclitaxel and docetaxel as assessed by MTT assay. Moreover, Western blot assay showed that eIF4E siRNA increased Bax/Bcl-2 ratio in MDA-MB-231 cells. Taken together, we showed that knockdown of eIF4E suppressed cell growth and migration, enhanced chemosensitivity, suggesting a potential therapeutic target in TN breast carcinoma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20652449     DOI: 10.1007/s12032-010-9630-0

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  31 in total

1.  Switching to aromatase inhibitors in early breast cancer.

Authors:  Francesco Boccardo; Alessandra Rubagotti
Journal:  Lancet       Date:  2007-02-17       Impact factor: 79.321

2.  2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

Authors:  Ian Smith; Marion Procter; Richard D Gelber; Sébastien Guillaume; Andrea Feyereislova; Mitch Dowsett; Aron Goldhirsch; Michael Untch; Gabriella Mariani; Jose Baselga; Manfred Kaufmann; David Cameron; Richard Bell; Jonas Bergh; Robert Coleman; Andrew Wardley; Nadia Harbeck; Roberto I Lopez; Peter Mallmann; Karen Gelmon; Nicholas Wilcken; Erik Wist; Pedro Sánchez Rovira; Martine J Piccart-Gebhart
Journal:  Lancet       Date:  2007-01-06       Impact factor: 79.321

3.  Overexpression of eukaryotic initiation factor 4E (eIF4E) in breast carcinoma.

Authors:  B D Li; L Liu; M Dawson; A De Benedetti
Journal:  Cancer       Date:  1997-06-15       Impact factor: 6.860

4.  Eukaryotic initiation factor 4E overexpression in triple-negative breast cancer predicts a worse outcome.

Authors:  Anthony Flowers; Quyen D Chu; Lori Panu; Carol Meschonat; Gloria Caldito; Mary Lowery-Nordberg; Benjamin D L Li
Journal:  Surgery       Date:  2009-08       Impact factor: 3.982

Review 5.  Triple-negative breast cancer: risk factors to potential targets.

Authors:  Bryan P Schneider; Eric P Winer; William D Foulkes; Judy Garber; Charles M Perou; Andrea Richardson; George W Sledge; Lisa A Carey
Journal:  Clin Cancer Res       Date:  2008-12-15       Impact factor: 12.531

6.  Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity.

Authors:  Jeremy R Graff; Bruce W Konicek; Thomas M Vincent; Rebecca L Lynch; David Monteith; Spring N Weir; Phil Schwier; Andrew Capen; Robin L Goode; Michele S Dowless; Yuefeng Chen; Hong Zhang; Sean Sissons; Karen Cox; Ann M McNulty; Stephen H Parsons; Tao Wang; Lillian Sams; Sandaruwan Geeganage; Larry E Douglass; Blake Lee Neubauer; Nicholas M Dean; Kerry Blanchard; Jianyong Shou; Louis F Stancato; Julia H Carter; Eric G Marcusson
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

7.  Eukaryotic translation initiation factor 4E regulates expression of cyclin D1 at transcriptional and post-transcriptional levels.

Authors:  I B Rosenwald; R Kaspar; D Rousseau; L Gehrke; P Leboulch; J J Chen; E V Schmidt; N Sonenberg; I M London
Journal:  J Biol Chem       Date:  1995-09-08       Impact factor: 5.157

8.  eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling.

Authors:  Alpana Soni; Argun Akcakanat; Gopal Singh; David Luyimbazi; Yuhuan Zheng; Doyil Kim; Ana Gonzalez-Angulo; Funda Meric-Bernstam
Journal:  Mol Cancer Ther       Date:  2008-07       Impact factor: 6.261

9.  Tumor-specific RNAi targeting eIF4E suppresses tumor growth, induces apoptosis and enhances cisplatin cytotoxicity in human breast carcinoma cells.

Authors:  Ke Dong; Rui Wang; Xi Wang; Fang Lin; Jian-Jun Shen; Ping Gao; Hui-Zhong Zhang
Journal:  Breast Cancer Res Treat       Date:  2008-03-10       Impact factor: 4.872

Review 10.  The mRNA cap-binding protein eIF4E in post-transcriptional gene expression.

Authors:  Tobias von der Haar; John D Gross; Gerhard Wagner; John E G McCarthy
Journal:  Nat Struct Mol Biol       Date:  2004-06       Impact factor: 15.369

View more
  18 in total

1.  Prognostic significance of eukaryotic initiation factor 4E in hepatocellular carcinoma.

Authors:  Xue-Mei Jiang; Xiang-Nan Yu; Ren-Zheng Huang; Hai-Rong Zhu; Xiao-Peng Chen; Ju Xiong; Zheng-Yi Chen; Xiao-Xi Huang; Xi-Zhong Shen; Ji-Min Zhu
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-06       Impact factor: 4.553

Review 2.  Developing anti-neoplastic biotherapeutics against eIF4F.

Authors:  Jutta Steinberger; Jennifer Chu; Rayelle Itoua Maïga; Katia Sleiman; Jerry Pelletier
Journal:  Cell Mol Life Sci       Date:  2016-12-21       Impact factor: 9.261

Review 3.  Therapeutic Opportunities in Eukaryotic Translation.

Authors:  Jennifer Chu; Jerry Pelletier
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-06-01       Impact factor: 10.005

4.  Elevated levels of p-Mnk1, p-eIF4E and p-p70S6K proteins are associated with tumor recurrence and poor prognosis in astrocytomas.

Authors:  Weibing Fan; Weiyuan Wang; Xinfa Mao; Shuzhou Chu; Juan Feng; Desheng Xiao; Jianhua Zhou; Songqing Fan
Journal:  J Neurooncol       Date:  2016-11-29       Impact factor: 4.130

5.  Coexpression of Bcl-2 with epithelial-mesenchymal transition regulators is a prognostic indicator in hepatocellular carcinoma.

Authors:  Nan Zhao; Bao-cun Sun; Xiu-lan Zhao; Zhi-yong Liu; Tao Sun; Zhi-qiang Qiu; Qiang Gu; Na Che; Xue-yi Dong
Journal:  Med Oncol       Date:  2012-03-30       Impact factor: 3.064

6.  eIF4F suppression in breast cancer affects maintenance and progression.

Authors:  Z Nasr; F Robert; J A Porco; W J Muller; J Pelletier
Journal:  Oncogene       Date:  2012-04-09       Impact factor: 9.867

7.  Targeted Dual pH-Sensitive Lipid ECO/siRNA Self-Assembly Nanoparticles Facilitate In Vivo Cytosolic sieIF4E Delivery and Overcome Paclitaxel Resistance in Breast Cancer Therapy.

Authors:  Maneesh Gujrati; Amita M Vaidya; Margaret Mack; Dayton Snyder; Anthony Malamas; Zheng-Rong Lu
Journal:  Adv Healthc Mater       Date:  2016-10-10       Impact factor: 9.933

8.  Targeting of protein translation as a new treatment paradigm for prostate cancer.

Authors:  Vidya P Ramamurthy; Senthilmurugan Ramalingam; Andrew K Kwegyir-Afful; Arif Hussain; Vincent C O Njar
Journal:  Curr Opin Oncol       Date:  2017-05       Impact factor: 3.645

9.  Phospho-4e-BP1 and eIF4E overexpression synergistically drives disease progression in clinically confined clear cell renal cell carcinoma.

Authors:  Lee Campbell; Bharat Jasani; David Fr Griffiths; Mark Gumbleton
Journal:  Am J Cancer Res       Date:  2015-08-15       Impact factor: 6.166

10.  Transcriptomic and proteomic profiling of maize embryos exposed to camptothecin.

Authors:  Nuria Sánchez-Pons; Sami Irar; Nora García-Muniz; Carlos M Vicient
Journal:  BMC Plant Biol       Date:  2011-05-19       Impact factor: 4.215

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.